Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia.
Discipline of Child and Adolescent Health, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Eur J Pediatr. 2021 Sep;180(9):2711-2721. doi: 10.1007/s00431-021-04066-3. Epub 2021 Apr 11.
Surfactant, which was first identified in the 1920s, is pivotal to lower the surface tension in alveoli of the lungs and helps to lower the work of breathing and prevents atelectasis. Surfactant proteins, such as surfactant protein B and surfactant protein C, contribute to function and stability of surfactant film. Additionally, adenosine triphosphate binding cassette 3 and thyroid transcription factor-1 are also integral for the normal structure and functioning of pulmonary surfactant. Through the study and improved understanding of surfactant over the decades, there is increasing interest into the study of childhood interstitial lung diseases (chILD) in the context of surfactant protein disorders. Surfactant protein deficiency syndrome (SPDS) is a group of rare diseases within the chILD group that is caused by genetic mutations of SFTPB, SFTPC, ABCA3 and TTF1 genes.Conclusion: This review article seeks to provide an overview of surfactant protein disorders in the context of chILD. What is Known: • Surfactant protein disorders are an extremely rare group of disorders caused by genetic mutations of SFTPB, SPTPC, ABCA3 and TTF1 genes. • Given its rarity, research is only beginning to unmask the pathophysiology, inheritance, spectrum of disease and its manifestations. What is New: • Diagnostic and treatment options continue to be explored and evolve in these conditions. • It is, therefore, imperative that we as paediatricians are abreast with current development in this field.
表面活性剂于 20 世纪 20 年代首次被发现,对于降低肺部肺泡的表面张力至关重要,有助于降低呼吸功并防止肺不张。表面活性蛋白,如表面活性蛋白 B 和表面活性蛋白 C,有助于表面活性剂膜的功能和稳定性。此外,三磷酸腺苷结合盒 3 和甲状腺转录因子 1 对于肺表面活性剂的正常结构和功能也是必不可少的。通过几十年来对表面活性剂的研究和深入了解,人们对表面活性剂蛋白紊乱相关儿童间质性肺疾病(chILD)的研究兴趣日益增加。表面活性剂蛋白缺乏综合征(SPDS)是 chILD 组中一组罕见的疾病,由 SFTPB、SFTPC、ABCA3 和 TTF1 基因突变引起。
本文旨在概述 chILD 背景下的表面活性剂蛋白紊乱。
表面活性剂蛋白紊乱是一组由 SFTPB、SFTPC、ABCA3 和 TTF1 基因突变引起的极其罕见的疾病。
由于其罕见性,研究才刚刚开始揭示其病理生理学、遗传、疾病谱及其表现。
在这些情况下,诊断和治疗选择仍在不断探索和发展。
因此,我们儿科医生必须了解该领域的最新发展。